Skip to main content
profile image
Selected Works of Samer Nakhle, MD, FACE
Article
Tildacerfont for the Treatment of Patients With Classic Congenital Adrenal Hyperplasia: Results From a 12-Week Phase 2 Clinical Trial in Adults With Classic CAH
Journal of the Endocrine Society (2021)
  • Richard Joseph Auchus, University of Michigan
  • Deborah P Merke, National Institutes of Health
  • Ivy-Joan Madu, Diabetes Associates Medical Group, Orange, CA, USA
  • Samer Nakhle, Palm Medical Group, Las Vegas, NV, USA
  • Kyriakie Sarafoglou, University of Minnesota
  • Michael Huang, former employee of Spruce Biosciences, Daly City, CA, USA
  • David Moriarty, Spruce Biosciences, Daly City, CA, USA
  • Chris Barnes, Spruce Biosciences, Daly City, CA, USA
  • Ron S Newfield, University of California, San Diego
Link
Disciplines
Publication Date
May 3, 2021
DOI
10.1210/JENDSO/BVAB048.1011
Citation Information
Richard Joseph Auchus, Deborah P Merke, Ivy-Joan Madu, Samer Nakhle, et al.. "Tildacerfont for the Treatment of Patients With Classic Congenital Adrenal Hyperplasia: Results From a 12-Week Phase 2 Clinical Trial in Adults With Classic CAH" Journal of the Endocrine Society Vol. 5 (2021)
Available at: http://works.bepress.com/samer-nakhle/4/